Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
Background: The treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) with omalizumab has been well studied based on clinical evaluation. Nevertheless, ideal quantitative or qualitative biomarkers for predicting a different response to biologics urgently need to be explored. We a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455124001418 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526290604097536 |
|---|---|
| author | Yutong Sima, MD Ming Zheng, MD Yan Zhao, PhD Siqi Ge, PhD Chengyao Liu, MD Ping Wang, BS Xiangdong Wang, MD, PhD Luo Zhang, MD, PhD |
| author_facet | Yutong Sima, MD Ming Zheng, MD Yan Zhao, PhD Siqi Ge, PhD Chengyao Liu, MD Ping Wang, BS Xiangdong Wang, MD, PhD Luo Zhang, MD, PhD |
| author_sort | Yutong Sima, MD |
| collection | DOAJ |
| description | Background: The treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) with omalizumab has been well studied based on clinical evaluation. Nevertheless, ideal quantitative or qualitative biomarkers for predicting a different response to biologics urgently need to be explored. We aim to identify potential biomarkers for predicting a good or poor response in patients with refractory CRSwNP. Methodology: Patients received an endoscopic and radiological evaluation, a visual analogue scale (VAS) assessment, and a 22-item sinonasal outcome test (SNOT-22). Forty-eight biomarkers involving type 1 (T1), type 2 (T2), and type 3 (T3) inflammatory factors, chemokines, and remodeling factors were detected in nasal secretion and serum samples at baseline and after 24 weeks of omalizumab treatment. Results: Eighteen patients with CRSwNP and 16 patients as control were enrolled. Patients with CRSwNP who received oamlizumab treatment with the SNOT-22 and VAS scores improved by 8.9 and 2 points in 72.22% and 50%, respectively. The nasal polyp score (NPS) and Lund-Mackay score were significantly improved in 55.56% of patients. The concentrations of T2 inflammatory biomarker, granulocyte-macrophage colony-stimulating factor (GM-CSF), T3 inflammatory biomarkers, granulocyte colony-stimulating factor (G-CSF), chemokine (C-X-C motif) ligand (CXCL)-1, and chemokine (C–C motif) ligand-20 (CCL-20), T1 inflammatory biomarker, IP-10 (CXCL-10), and granzyme B in nasal secretion and serum periostin were significantly decreased. Serum CCL-3 (AUC = 0.836) and CCL-4 (AUC = 0.909) levels predicted the improvement of SNOT-22 score, respectively. Serum IL-8 (AUC = 0.883) predicted poor improvement in nasal congestion score. Nasal secretion CXCL-1 (AUC = 0.812), GM-CSF (AUC = 0.813), IgE (AUC = 0.900) and IP-10 (AUC = 0.800) effectively predicted none or less improvement in nasal polyp score. Conclusions: Omalizumab remarkably affects inflammatory mediators in different pathways. CCL-3 and CCL-4 in serum and IgE, CXCL-1, GM-CSF, and IP-10 in nasal secretion may be considered as preferable biomarkers for predicting favorable or ineffective response to omalizumab therapy in patients with refractory CRSwNP comorbid with asthma, based on various clinical indicators. |
| format | Article |
| id | doaj-art-a41530d2b11c4e1ea39f0c7ce166b9e0 |
| institution | Kabale University |
| issn | 1939-4551 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj-art-a41530d2b11c4e1ea39f0c7ce166b9e02025-01-17T04:49:15ZengElsevierWorld Allergy Organization Journal1939-45512025-01-01181101009Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkersYutong Sima, MD0Ming Zheng, MD1Yan Zhao, PhD2Siqi Ge, PhD3Chengyao Liu, MD4Ping Wang, BS5Xiangdong Wang, MD, PhD6Luo Zhang, MD, PhD7Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, ChinaDepartment of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China; Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Corresponding author. Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China; Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing 100005, China; Corresponding author. Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.Background: The treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) with omalizumab has been well studied based on clinical evaluation. Nevertheless, ideal quantitative or qualitative biomarkers for predicting a different response to biologics urgently need to be explored. We aim to identify potential biomarkers for predicting a good or poor response in patients with refractory CRSwNP. Methodology: Patients received an endoscopic and radiological evaluation, a visual analogue scale (VAS) assessment, and a 22-item sinonasal outcome test (SNOT-22). Forty-eight biomarkers involving type 1 (T1), type 2 (T2), and type 3 (T3) inflammatory factors, chemokines, and remodeling factors were detected in nasal secretion and serum samples at baseline and after 24 weeks of omalizumab treatment. Results: Eighteen patients with CRSwNP and 16 patients as control were enrolled. Patients with CRSwNP who received oamlizumab treatment with the SNOT-22 and VAS scores improved by 8.9 and 2 points in 72.22% and 50%, respectively. The nasal polyp score (NPS) and Lund-Mackay score were significantly improved in 55.56% of patients. The concentrations of T2 inflammatory biomarker, granulocyte-macrophage colony-stimulating factor (GM-CSF), T3 inflammatory biomarkers, granulocyte colony-stimulating factor (G-CSF), chemokine (C-X-C motif) ligand (CXCL)-1, and chemokine (C–C motif) ligand-20 (CCL-20), T1 inflammatory biomarker, IP-10 (CXCL-10), and granzyme B in nasal secretion and serum periostin were significantly decreased. Serum CCL-3 (AUC = 0.836) and CCL-4 (AUC = 0.909) levels predicted the improvement of SNOT-22 score, respectively. Serum IL-8 (AUC = 0.883) predicted poor improvement in nasal congestion score. Nasal secretion CXCL-1 (AUC = 0.812), GM-CSF (AUC = 0.813), IgE (AUC = 0.900) and IP-10 (AUC = 0.800) effectively predicted none or less improvement in nasal polyp score. Conclusions: Omalizumab remarkably affects inflammatory mediators in different pathways. CCL-3 and CCL-4 in serum and IgE, CXCL-1, GM-CSF, and IP-10 in nasal secretion may be considered as preferable biomarkers for predicting favorable or ineffective response to omalizumab therapy in patients with refractory CRSwNP comorbid with asthma, based on various clinical indicators.http://www.sciencedirect.com/science/article/pii/S1939455124001418Chronic rhinosinusitis with nasal polypsOmalizumabEndotypePrediction |
| spellingShingle | Yutong Sima, MD Ming Zheng, MD Yan Zhao, PhD Siqi Ge, PhD Chengyao Liu, MD Ping Wang, BS Xiangdong Wang, MD, PhD Luo Zhang, MD, PhD Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers World Allergy Organization Journal Chronic rhinosinusitis with nasal polyps Omalizumab Endotype Prediction |
| title | Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| title_full | Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| title_fullStr | Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| title_full_unstemmed | Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| title_short | Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| title_sort | predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers |
| topic | Chronic rhinosinusitis with nasal polyps Omalizumab Endotype Prediction |
| url | http://www.sciencedirect.com/science/article/pii/S1939455124001418 |
| work_keys_str_mv | AT yutongsimamd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT mingzhengmd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT yanzhaophd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT siqigephd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT chengyaoliumd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT pingwangbs predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT xiangdongwangmdphd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers AT luozhangmdphd predictingtheeffectivenessofomalizumabinpatientswithrefractorychronicrhinosinusitiswithnasalpolypscomorbidwithasthmabasedoninflammatorybiomarkers |